Open AccessCD5 + B cells and naturally occurring autoantibodies in cancer patients
Author(s) -
STEIN R.,
WITZ I. P.,
OVADlA J,
GOLDENBERG D. M.,
YRON I.
Publication year - 1991
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1991.tb05742.x
Subject(s) - cd5 , autoantibody , cd19 , immunology , cancer , antibody , population , medicine , b cell , biology , environmental health
SUMMARY We have determined the percentage of CD5 + B lymphocytes in the peripheral blood of cancer patients and healthy controls, using antibodies directed at the CDS and CD 19 ( pan‐ B) markers. The frequencies of CD5 + B cells, expressed as a percentage of total B cells, ranged from 14.3 to 57.5% in the controls and from 14.8 to 82.8% in the patient population. One‐third of the cancer patients had frequencies > 2 s.d. above the mean of the control population. The CD5 + B cell fraction expressed as a percentage of total lymphocytes was also significantly elevated in this group of cancer patients. These results suggest that the CD5 + B cell compartment may be affected by the malignant process or by the therapy modality employed. The plasma levels of several naturally occurring autoantibodies, the products of the CD5 + B cells, were also assessed in cancer patients and controls. No significant differences were observed when reactivity to several autoantigens was measured. These included nuclear components and phospholipids.